Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivermectin + permethrin-University Ghent-scabies refers to the comparative clinical evaluation of oral ivermectin and topical permethrin for the treatment of scabies, a skin infestation caused by the mite *Sarcoptes scabiei*. This specific context originates from a Phase 2 clinical trial (NCT00300716) sponsored by University Ghent, which utilized a double-blind, double-dummy design to assess whether a single administration of either agent provided sufficient efficacy. Ivermectin is an anthelmintic small molecule that induces parasite paralysis by activating glutamate-gated chloride channels. Permethrin is a synthetic pyrethroid neurotoxin that disrupts voltage-gated sodium channels, leading to prolonged depolarization and death of the mite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ivermectin + permethrin.